Ignorance is Bliss – for Teva

I did not pay much attention to the fairly recent panel decision in Bristol-Myers Squibb Co. v. Teva Pharma. USA, 757 F.3d 967 (Fed. Cir. 2014). It seemed like a fairly routine panel affirmance of the district court’s finding that Bristol-Myers’ patent (5206244) on the nucleoside analog entecavir was obvious in view of a structurally similar [...]

The post Ignorance is Bliss – for Teva appeared first on Biotechnology Patent Law Blog | Patents4Life by Warren Woessner.